Table 1 Characteristics and molecular responses of CML-patients.

^a)Patients 7 and 13 had similar responses at both 6 and 18 months.

Abbreviations: CP, chronic phase; BC, blast crisis; BrCa, breast cancer; C, complete; Ma, major; Mi, minor; I, Imatinib; N, Nilotinib; D, Dasatinib; R, Responsive; NR, not-responsive; NE, not-evaluated; Int, intermediate; BMA, bone marrow aplasia.

Blood Res 2015;50:154~159 https://doi.org/10.5045/br.2015.50.3.154